M1 Macrophage-related Gene Model for NSCLC Immunotherapy Response Prediction

Overview

Journal Acta Biochim Biophys Sin (Shanghai)

Specialties Biochemistry
Biophysics

Date 2024 Feb 21

PMID 38379417

Authors

Sifan Wu

Qiqi Sheng

Pengjun Liu

Zhe Jiao

Jinru Lv

Rong Qiao

Dongkun Xie

Zanhan Wang

Jiamei Ge

Penghui Li

Tiaoxia Wei

Jie Lei

Jieyi Fan

Liang Wang

Affiliations

Soon will be listed here.

Abstract

Patients diagnosed with non-small cell lung cancer (NSCLC) have a limited lifespan and exhibit poor immunotherapy outcomes. M1 macrophages have been found to be essential for antitumor immunity. This study aims to develop an immunotherapy response evaluation model for NSCLC patients based on transcription. RNA sequencing profiles of 254 advanced-stage NSCLC patients treated with immunotherapy are downloaded from the POPLAR and OAK projects. Immune cell infiltration in NSCLC patients is examined, and thereafter, different coexpressed genes are identified. Next, the impact of M1 macrophage-related genes on the prognosis of NSCLC patients is investigated. Six M1 macrophage coexpressed genes, namely, , , , , , and , exhibit a strong association with the prognosis of NSCLC and serve as effective predictors for immunotherapy response. A response model is constructed using a Cox regression model and Lasso Cox regression analysis. The M1 genes are validated in our TD-FOREKNOW NSCLC clinical trial by RT-qPCR. The response model shows excellent immunotherapy response prediction and prognosis evaluation value in advanced-stage NSCLC. This model can effectively predict advanced NSCLC prognosis and aid in identifying patients who could benefit from customized immunotherapy as well as sensitive drugs.

Citing Articles

Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas.

Zhao Y, Zhou C, Zuo L, Yan H, Gu Y, Liu H BMC Cancer. 2025; 25(1):36.

PMID: 39780110 PMC: 11707868. DOI: 10.1186/s12885-024-13395-z.

Selective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens.

Fischer J, Shutta K, Chen C, Fanfani V, Saha E, Mandros P bioRxiv. 2024; .

PMID: 39345481 PMC: 11430018. DOI: 10.1101/2024.09.19.613876.

References

Jia M, Jia X, Zhang D, Liu W, Yi S, Li Z . CD2 T-helper 17-like cells differentiated from a CD133 subpopulation of non-small cell lung carcinoma cells promote the growth of lung carcinoma. Ann Transl Med. 2021; 9(8):687. PMC: 8106049. DOI: 10.21037/atm-21-980. View

Gunassekaran G, Vadevoo S, Baek M, Lee B . M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278:121137. DOI: 10.1016/j.biomaterials.2021.121137. View

Schicht M, Rausch F, Finotto S, Mathews M, Mattil A, Schubert M . SFTA3, a novel protein of the lung: three-dimensional structure, characterisation and immune activation. Eur Respir J. 2014; 44(2):447-56. DOI: 10.1183/09031936.00179813. View

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y . Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A. 2012; 109(6):2066-71. PMC: 3277567. DOI: 10.1073/pnas.1113099109. View

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P . Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017; 14(7):399-416. PMC: 5480600. DOI: 10.1038/nrclinonc.2016.217. View

Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F . Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. JAMA Oncol. 2023; 9(10):1348-1355. PMC: 10401395. DOI: 10.1001/jamaoncol.2023.2751. View

Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing K . IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018; 15(5):447-457. PMC: 6068130. DOI: 10.1038/cmi.2017.143. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

10.

Barnes T, Amir E . HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2018; 118(2):e5. PMC: 5785752. DOI: 10.1038/bjc.2017.417. View

11.

Cheng Y, Wang S, Liu J, Jin L, Liu Y, Li C . Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. Cell Prolif. 2020; 53(8):e12865. PMC: 7445401. DOI: 10.1111/cpr.12865. View

12.

Pan Y, Yu Y, Wang X, Zhang T . Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020; 11:583084. PMC: 7751482. DOI: 10.3389/fimmu.2020.583084. View

13.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

14.

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H . Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019; 11(1):34. PMC: 6534875. DOI: 10.1186/s13073-019-0638-6. View

15.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

16.

Chen Y, Hao Q, Wang S, Cao M, Huang Y, Weng X . Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP. Proc Natl Acad Sci U S A. 2021; 118(29). PMC: 8307289. DOI: 10.1073/pnas.2026813118. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

19.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

20.

Li B, Smit E, Goto Y, Nakagawa K, Udagawa H, Mazieres J . Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2021; 386(3):241-251. PMC: 9066448. DOI: 10.1056/NEJMoa2112431. View